Stock Price
217.20
Daily Change
-8.10 -3.60%
Monthly
-6.66%
Yearly
-3.77%
Q1 Forecast
210.90



Peers Price Chg Day Year Date
Avita Medical 1.37 -0.01 -0.72% -47.51% Mar/06
Akebia Therapeutics 1.27 0.08 6.72% -33.16% Mar/06
Tectonic Therapeutic 35.87 8.02 28.80% 54.75% Mar/06
Ionis Pharmaceuticals 74.04 -1.12 -1.49% 118.99% Mar/06
IQVIA Holdings 174.49 -4.01 -2.25% -8.94% Mar/06
Dianthus Therapeutics 65.20 3.77 6.14% 171.33% Mar/06
Moderna 52.52 -1.31 -2.43% 47.49% Mar/06
Organon & Co 6.56 -0.15 -2.24% -57.50% Mar/06
Revvity 91.34 -5.23 -5.42% -22.30% Mar/06
Sartorius 217.20 -8.10 -3.60% -3.77% Mar/07

Indexes Price Day Year Date
EU600 599 -6.14 -1.02% 8.20% Mar/06
DE Mid 29483 -206.18 -0.69% -0.26% Mar/06

Sartorius traded at 217.20 this Saturday March 7th, decreasing 8.10 or 3.60 percent since the previous trading session. Looking back, over the last four weeks, Sartorius lost 6.66 percent. Over the last 12 months, its price fell by 3.77 percent. Looking ahead, we forecast Sartorius to be priced at 210.90 by the end of this quarter and at 193.08 in one year, according to Trading Economics global macro models projections and analysts expectations.

Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. It operates through two segments: Bioprocess Solutions and Lab Products and Services. The Bioprocess Solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, and filter technology for clarification, among others. The Lab Products and Services segment provides instruments, consumables and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation and membrane filter systems for sterility testing of parenterals.